Eric Schmidt
Stock Analyst at Cantor Fitzgerald
(2.96)
# 1,386
Out of 5,135 analysts
53
Total ratings
30%
Success rate
6.46%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Eric Schmidt
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| LEGN Legend Biotech | Maintains: Overweight | $75 → $74 | $18.35 | +303.27% | 3 | Dec 17, 2025 | |
| VSTM Verastem | Assumes: Overweight | n/a | $5.71 | - | 1 | Oct 16, 2025 | |
| ACLX Arcellx | Assumes: Neutral | $88 | $69.04 | +27.46% | 1 | Oct 9, 2025 | |
| SMMT Summit Therapeutics | Reiterates: Overweight | n/a | $15.88 | - | 3 | Sep 8, 2025 | |
| SRRK Scholar Rock Holding | Initiates: Overweight | n/a | $46.96 | - | 1 | Jul 17, 2025 | |
| RNA Avidity Biosciences | Reiterates: Overweight | $96 | $72.83 | +31.81% | 5 | Jun 27, 2025 | |
| PRTA Prothena Corporation | Reiterates: Neutral | n/a | $9.09 | - | 2 | Jun 20, 2025 | |
| IMTX Immatics | Reiterates: Overweight | n/a | $9.95 | - | 4 | Apr 1, 2025 | |
| ALMS Alumis | Reiterates: Overweight | n/a | $27.51 | - | 4 | Mar 20, 2025 | |
| BCAX Bicara Therapeutics | Reiterates: Overweight | $13 | $14.49 | -10.21% | 2 | Mar 13, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | n/a | $4.13 | - | 2 | Mar 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Neutral | n/a | $53.52 | - | 4 | Feb 19, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Neutral | n/a | $102.99 | - | 6 | Jan 10, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | n/a | $27.56 | - | 4 | Dec 18, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | n/a | $12.41 | - | 3 | Dec 5, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | n/a | $32.50 | - | 2 | Sep 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $292 | $194.13 | +50.41% | 3 | Sep 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $370 | $470.31 | -21.33% | 1 | Oct 17, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $1.72 | - | 1 | Oct 17, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | n/a | $1.46 | - | 1 | May 30, 2017 |
Legend Biotech
Dec 17, 2025
Maintains: Overweight
Price Target: $75 → $74
Current: $18.35
Upside: +303.27%
Verastem
Oct 16, 2025
Assumes: Overweight
Price Target: n/a
Current: $5.71
Upside: -
Arcellx
Oct 9, 2025
Assumes: Neutral
Price Target: $88
Current: $69.04
Upside: +27.46%
Summit Therapeutics
Sep 8, 2025
Reiterates: Overweight
Price Target: n/a
Current: $15.88
Upside: -
Scholar Rock Holding
Jul 17, 2025
Initiates: Overweight
Price Target: n/a
Current: $46.96
Upside: -
Avidity Biosciences
Jun 27, 2025
Reiterates: Overweight
Price Target: $96
Current: $72.83
Upside: +31.81%
Prothena Corporation
Jun 20, 2025
Reiterates: Neutral
Price Target: n/a
Current: $9.09
Upside: -
Immatics
Apr 1, 2025
Reiterates: Overweight
Price Target: n/a
Current: $9.95
Upside: -
Alumis
Mar 20, 2025
Reiterates: Overweight
Price Target: n/a
Current: $27.51
Upside: -
Bicara Therapeutics
Mar 13, 2025
Reiterates: Overweight
Price Target: $13
Current: $14.49
Upside: -10.21%
Mar 7, 2025
Reiterates: Overweight
Price Target: n/a
Current: $4.13
Upside: -
Feb 19, 2025
Reiterates: Neutral
Price Target: n/a
Current: $53.52
Upside: -
Jan 10, 2025
Reiterates: Neutral
Price Target: n/a
Current: $102.99
Upside: -
Dec 18, 2024
Reiterates: Overweight
Price Target: n/a
Current: $27.56
Upside: -
Dec 5, 2024
Reiterates: Overweight
Price Target: n/a
Current: $12.41
Upside: -
Sep 9, 2024
Reiterates: Overweight
Price Target: n/a
Current: $32.50
Upside: -
Sep 9, 2024
Reiterates: Overweight
Price Target: $292
Current: $194.13
Upside: +50.41%
Oct 17, 2023
Reiterates: Overweight
Price Target: $370
Current: $470.31
Upside: -21.33%
Oct 17, 2023
Downgrades: Neutral
Price Target: n/a
Current: $1.72
Upside: -
May 30, 2017
Initiates: Outperform
Price Target: n/a
Current: $1.46
Upside: -